Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Vivos Therapeutics, Inc. reported revenue of $17M, up 16.0% year over year. Operating margin was -114.1% and net margin -121.4%, on a free-cash-flow margin of -100.9% with capital expenditure at 13.4% of revenue. Every figure is computed directly from VVOS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $17M | -114.1% | -121.4% |
| FY2024 | $15M | -74.3% | -74.1% |
| FY2023 | $14M | -125.3% | -98.4% |
| FY2022 | $16M | -156.2% | -148.8% |
| FY2021 | $17M | -120.7% | -120.2% |
How does VVOS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.